Ads
related to: list of p450 inhibitors for prostate cancer- Dosing & Administration
Learn About Dosing Considerations
For This Targeted Treatment.
- Safety Profile
Physicians, See Safety
Information About This Treatment.
- Efficacy Information
Physicians, See How A Targeted
Treatment May Help Your Patients.
- Physician Resources
Download The Patient Brochure &
Other Helpful Resources Here.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
"INHIBITORS, INDUCERS AND SUBSTRATES OF CYTOCHROME P450 ISOZYMES". "The Life Raft Group: Long List of Inhibitors and Inducers of CYP3A4 and CYP2D6". "DRUGBANK Online: Cytochrome P-450 Enzyme Inhibitors". "MEDICATIONS METABOLIZED BY CYTOCHROME P450 3A4" (PDF)
Prostate cancer: Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy Docetaxel: IV: As above. Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.
AIs are divided into two categories, steroidal aromatase inhibitors (SAIs, type 1 inhibitors) and non-steroidal aromatase inhibitors (type 2 inhibitors) that is based on their mechanism of action and structure. NSAIs are mainly used to treat breast cancer in women.
In 2011, the FDA approved the CYP17A1 inhibitor, abiraterone, which contains a steroidal scaffold that is similar to the endogenous CYP17A1 substrates, with prednisone for the treatment of castration-resistant prostate cancer. Abiraterone is structurally similar to the substrates of other cytochrome P450 enzymes involved in steroidogenesis, and ...
Cytochrome P450 inhibitors is a category of agents that inhibit Cytochrome P450. Subcategories. This category has the following 8 subcategories, out of 8 total. A.
Proadifen (SKF-525A) is a non-selective inhibitor of cytochrome P450 enzymes, preventing some types of drug metabolism. [1] It is also an inhibitor of neuronal nitric oxide synthase (NOS), CYP-dependent (cytochrome P450-dependent) arachidonate metabolism, transmembrane calcium influx, and platelet thromboxane synthesis.
Ads
related to: list of p450 inhibitors for prostate cancer